Press releases

13 May 2022

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

10 May 2022

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

2 May 2022

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

28 Apr 2022

UCB’s General Meeting of Shareholders 2022

22 Apr 2022

Disposal of own shares

15 Apr 2022

Disposal of own shares

Press releases

Press releases

Search Press releases

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

UCB’s General Meeting of Shareholders 2022

Disposal of own shares

Disposal of own shares

Choose a Country

UCB Belgium: A global hub of healthcare innovation

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Sustainability – Click here to learn more about our sustainable approach

UCBCares® - Discover what UCBCares® is about and the services they offer

Advancing Our Gene Therapy Journey

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant...

UCB completes sale of established brands and updates 2024 financial guidance

UCB completes sale of established brands and updates 2024 financial guidance

Half-year results 2024: strong start into UCB’s decade of growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

UCB’s General Meeting of Shareholders 2022

Disposal of own shares

Disposal of own shares

Choose a Country